Biotech Hangout
Episode 99
Apr 30, 2024
Biotech Hangout hosts discuss Biden's capital gains tax proposal, FTC's non-compete ban, Q1 earnings reports, Acrivon's oncology data, ImmunityBio's FDA approval, and financings like Xaira Therapeutics $1B raise. They also debate liked vs unliked CEOs and delve into innovative biotech approaches in depression and obesity treatment, as well as biotech deals and investments.
59:23
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Biden's proposal to increase capital gains tax and tax unrealized gains could impact private company owners financially.
- FTC's ban on non-compete clauses affects 30 million US workers, excluding high-earning executives from enforcement.
Deep dives
Biden's Tax Proposal Impact on Capitol Gains and Unrealized Gains
Biden's proposal to increase capital gains tax to 44.6 percent and tax unrealized gains at 25% could have significant implications. This proposal raises concerns about taxing individuals on unrealized gains in private companies, impacting their finances even without cash liquidity.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
